Develops inhaled therapies for respiratory diseases, focusing on novel drug delivery technologies.
Pulmatrix, Inc., headquartered in Lexington, Massachusetts, is a pioneering clinical-stage biotechnology company specializing in the discovery and development of inhaled therapies. Focused primarily on addressing respiratory and other diseases with significant unmet medical needs, Pulmatrix leverages its proprietary iSPERSE (inhaled small particles easily respirable and emitted) technology platform. This innovative platform facilitates the effective delivery of both small molecule and large molecule drugs directly to the lungs via inhalation, enabling localized or systemic therapeutic applications.
The company's robust pipeline includes Pulmazole, an inhaled anti-fungal medication designed for treating allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis patients. Additionally, Pulmatrix is advancing PUR1800, a narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for stable moderate-severe chronic obstructive pulmonary disease (COPD). PUR3100, another promising candidate, utilizes the iSPERSE formulation to deliver dihydroergotamine for the acute treatment of migraines.
Founded in 2003, Pulmatrix collaborates extensively within the biopharmaceutical industry through strategic partnerships and licensing agreements. These include collaborations with RespiVert Ltd. for access to kinase inhibitor drug candidates and a development and commercialization partnership with Cipla Technologies LLC for Pulmazole. With a commitment to advancing inhalation therapies that improve patient outcomes, Pulmatrix continues to push the boundaries of respiratory medicine through innovative research and development initiatives.